anti ang2 monoclonal antibody medi 3617

Drug Overview

The medication known as anti ang2 monoclonal antibody medi 3617 (also identified as MEDI3617) is a fully human, high-precision monoclonal antibody designed to combat cancer by starving tumors of their blood supply. It is classified as an angiogenesis inhibitor that specifically targets the “vascular destabilization” pathway used by tumors to expand.

While many cancer drugs target the VEGF protein, MEDI-3617 takes a different approach by targeting Angiopoietin-2 (Ang2). By blocking this specific protein, the drug aims to prevent the chaotic remodeling of blood vessels that allows cancer cells to thrive and spread.

• Generic Name: Anti-ANG2 monoclonal antibody MEDI-3617.
• Drug Class: Fully Human IgG1κ Monoclonal Antibody / Angiogenesis Inhibitor.
• Target: Angiopoietin-2 (Ang2).
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Discontinued. As of 2026, MEDI-3617 is not FDA-approved. Following Phase I/Ib clinical trials that showed limited clinical activity as a single agent, further development of this specific molecule was halted.

What Is It and How Does It Work? (Mechanism of Action)

The Ang2-Tie2 Signaling Pathway

Normal blood vessels are kept stable by a balance of proteins. Tumors upset this balance by producing high levels of Angiopoietin-2 (Ang2). Ang2 binds to the Tie2 receptor on endothelial cells, causing the vessels to become unstable and “leaky.” This unstable environment allows pro-angiogenic factors (like VEGF) to stimulate the growth of new, chaotic tumor vessels.

Molecular Level Mechanisms

1. Selective Binding: MEDI-3617 circulates in the blood and binds with high affinity (selectivity) to the Ang2 protein.
2. Ligand Neutralization: By “locking onto” Ang2, the antibody prevents it from binding to its natural receptor, Tie2.
3. Vessel Stabilization: Without the Ang2 “destabilizing” signal, the blood vessels are less likely to undergo the chaotic remodeling required for tumor growth.
4. Inhibition of Tumor Growth: By blocking the formation of new blood vessels (angiogenesis) and increasing tumor hypoxia (oxygen starvation), the drug inhibits the proliferation of tumor cells.

FDA-Approved Clinical Indications

There are currently no FDA-approved indications for MEDI-3617.

During its clinical life, it was investigated in Phase I and Phase Ib studies for:

• Advanced Solid Tumors: For patients whose cancer had not responded to standard therapy.
• Platinum-Resistant Ovarian Cancer: Investigated as a single agent and in combination.
• Malignant Glioma: Specifically bevacizumab-refractory cases.
• Metastatic Melanoma: Evaluated in combination with the immunotherapy tremelimumab.

Dosage and Administration Protocols

Because MEDI-3617 was an investigational agent, there is no “standard” clinical dose. The following protocols were established during its Phase I dose-escalation research.

Clinical Efficacy and Research Results

Clinical data from its Phase I trials (concluded and published around 2018–2021) provided the following insights:

• Safety Profile: MEDI-3617 was generally found to be safe and well-tolerated across many tumor types, particularly when used in combination with chemotherapy or other anti-angiogenic agents.
• Clinical Activity: While the drug showed it could successfully hit its target (Ang2), the “objective response rates” (significant tumor shrinkage) were modest. For instance, in ovarian cancer and glioma monotherapy expansion arms, the response rates were 6% and 0%, respectively.
• Development Status: On the basis of this limited single-agent activity, clinical development for MEDI-3617 was discontinued in favor of other therapeutic candidates.

Safety Profile and Side Effects

As a targeted antibody, MEDI-3617 avoids the harsh systemic toxicity of traditional chemotherapy, but it has a specific set of side effects related to vascular regulation.

Common Side Effects:

• Fatigue: Reported in approximately 24% of patients.
• Gastrointestinal Issues: Nausea and diarrhea (approx. 19%).
• Dysgeusia: Distortion of the sense of taste.
• Headache.

Serious/Unique Adverse Events:

• Peripheral Edema: Significant swelling in the limbs. In ovarian cancer trials, this side effect was particularly severe and prolonged (Grade 3), identifying a new safety signal for this class of drugs.
• Pleural Effusion: Fluid buildup around the lungs.
• Lymphedema: Swelling due to lymph fluid blockage.
• Neutropenia: A drop in white blood cell counts (mostly observed in combination therapy).

Research Areas

In the realm of Stem Cell and Regenerative Medicine, the Ang2-Tie2 pathway remains a high-interest area. Although MEDI-3617 was discontinued in oncology, researchers use the data from these trials to study how Ang2 inhibition affects the “vascular niche” where stem cells live. By understanding how to stabilize blood vessels, scientists hope to develop regenerative therapies for chronic wounds and vascular diseases where “leaky” vessels are a primary cause of tissue damage.

Patient Management and Practical Recommendations

Pre-treatment Tests (Historically Required):

• Baseline Organ Function: Kidney and liver function tests.
• Karnofsky Performance Status: A score of ≥70 was typically required for clinical trial eligibility.
• Heart Health: Monitoring for pre-existing cardiovascular issues.

Precautions:

• Fluid Retention: Patients must be closely monitored for sudden weight gain or swelling (edema), which could signal a serious reaction to the drug.
• Wound Healing: Like other angiogenesis inhibitors, this drug could theoretically interfere with the body’s ability to heal after surgery.

“Do’s and Don’ts” List:

• DO report any sudden shortness of breath (a potential sign of pleural effusion).
• DO track daily weight to catch early signs of fluid retention.
• DON’T ignore persistent swelling in the ankles or hands.
• DON’T start any new medications without consulting your oncology team, as they may interact with the antibody’s metabolism.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. MEDI-3617 is an investigational agent that has been discontinued from active clinical development. It is not approved by the US Food and Drug Administration (FDA) for any indication. Always consult with a qualified oncologist regarding currently available and approved treatments for your specific condition.